Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Rising Pharmaceuticals SDR Email:
Why this fails: The prospect is an expert. They've seen this template 1,000 times. There's zero indication you understand their specific situation. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring compliance people" (job postings - everyone sees this)
Start: "Your Part D formulary (H3214) excludes 47 FDA-approved generics in the 8 therapeutic categories with highest shortage frequency" (CMS formulary database with contract number)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, facility addresses.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, deadlines already pulled, patterns already identified - whether they buy or not.
These messages demonstrate precise understanding of the prospect's current situation backed by verifiable government data. Every claim traces to specific databases with record numbers.
Target federally qualified health centers (FQHCs) with published P&T meeting minutes showing brand-only placement for cardiovascular categories where FDA has approved multiple generics. For FQHCs serving uninsured patients, brand-tier placement creates access barriers when patients can't afford copays - this reveals mission impact, not just cost savings.
The P&T meeting minutes reference shows deep research into their governance process. Connecting brand-tier placement to patient access barriers (not just cost) reveals understanding of their FQHC mission. The routing question is low-stakes and directly actionable. This surfaces a problem they may know about but haven't prioritized.
Target 340B contract pharmacies serving multiple covered entities during simultaneous FDA drug shortage alerts. Cross-reference HRSA 340B contract pharmacy directory with current FDA shortage database to identify pharmacies where supplier failure on critical medications would create patient access gaps across multiple vulnerable populations (Ryan White, Community Health Networks, etc.).
Four specific drugs in current shortage is verifiable and urgent. Naming 7 covered entities creates concrete stakes. The insight reveals their risk exposure (patient access gaps across multiple vulnerable populations) rather than just promoting products. The backup supplier question is directly actionable and low-commitment.
This play requires identification of contract pharmacies via HRSA 340B database cross-referenced with current FDA shortage list. Assumes Rising can identify specific covered entity relationships and count (publicly available via HRSA OPAIS).
The synthesis of covered entity count + simultaneous shortages is unique intelligence Rising can provide.Target Medicare Part D plans with formularies that exclude FDA-approved generics in the therapeutic categories experiencing highest shortage frequency (injectables, ophthalmics, dermatologics). When preferred generics go on backorder, these exclusions force members into prior authorization for brands, creating treatment delays and administrative burden.
Specific contract number (H3214) shows real research. The combination of 47 excluded generics + 8 shortage-prone categories + 23% PA rate creates a compelling data story. This reveals a formulary design vulnerability they may not see - when shortages hit, they have no fallback options approved. The routing question is easy and actionable.
Identify Medicare Part D formularies with zero approved generic alternatives in therapeutic categories currently under FDA shortage alerts. When their preferred brand goes on backorder, members face treatment gaps because the formulary has no fallback options - revealing a critical formulary design flaw.
Zero alternatives is stark and specific. The combination of 6 categories with active FDA alerts creates urgency. Treatment gaps (not just cost or admin burden) is the patient impact. The shortage response protocol question is directly actionable. This reveals a formulary design vulnerability they need to address immediately.
Target Medicare Part D plans requiring brand step therapy in therapeutic categories where FDA shortage alerts are currently active. When preferred generics go on backorder, members hit brand PA requirements instead of having generic alternatives available - creating treatment delays during critical supply shortages.
Specific contract H3214 shows research. The combination of step therapy requirements + active shortage alerts reveals a formulary design flaw they may not see. When shortages hit, their step therapy protocol forces patients into expensive brand PAs rather than alternative generics. The contingency tier question is directly actionable.
Target 340B covered entity hospitals whose last P&T committee formulary review predates FDA approval of multiple new generics in categories where they still have brand-only Tier 2 placement. Without annual review, their 340B program continues paying brand acquisition costs despite generic availability - revealing a process failure costing real dollars.
March 2023 date is specific and verifiable from published P&T minutes. The 18-month gap + 14 new FDA approvals reveals a process failure. This shows them a blind spot in their governance process that's costing their 340B program money. The P&T review scheduling question is directly actionable and low-stakes.
Target 340B contract pharmacies serving multiple covered entities during active drug shortage alerts. The combination of specific address, high entity count (7), and verifiable FDA shortage status shows this isn't a generic pitch - Rising has done the homework to understand their exact exposure.
Specific address and entity count shows real research. Ondansetron shortage is real and current concern. FDA notification zone is concrete regulatory risk. Question is easy routing, not a sales pitch. Complete actionability - the recipient can verify the 7 entities and shortage status in 60 seconds.
This play assumes Rising has identified contract pharmacies via HRSA 340B database cross-referenced with current FDA shortage list. The entity count (7) and specific address are publicly available via HRSA OPAIS directory.
The synthesis of entity count + current shortage status is unique intelligence Rising can provide.Target contract pharmacies serving multiple covered entities where several are in CMS Special Focus designation zones. During current ondansetron and morphine shortages, medication access gaps at Special Focus entities trigger enhanced CMS scrutiny and potential funding risk - creating urgency for backup supplier relationships.
Specific address and entity names show research. The 4 out of 7 ratio in Special Focus designation is alarming and specific. Two specific shortage drugs (ondansetron, morphine) create urgency. CMS funding risk is concrete consequence beyond just medication access. The awareness question is low-stakes routing.
This play assumes Rising can cross-reference HRSA 340B contract pharmacy data with CMS Special Focus facility designations and current FDA shortage alerts. Entity names and Special Focus status are publicly verifiable.
The synthesis of Special Focus overlap + shortage timing is unique intelligence.Target contract pharmacies serving multiple 340B covered entities during ondansetron shortage. Provide specific covered entity names and three exact alternative formulations with 340B pricing availability - helping them maintain medication access across vulnerable populations.
Specific covered entities named shows deep research. Three exact formulations with specs is actionable. 340B pricing mention shows understanding of their world. The ask for NDC numbers and pricing is low-commitment. However, this feels slightly promotional - "we have inventory" is still a pitch, though better than generic outreach.
This play assumes Rising can identify specific covered entities served by contract pharmacies (publicly available via HRSA OPAIS) and match against their available product portfolio with current inventory levels.
The synthesis of specific covered entities + available formulations is actionable intelligence.Target 340B covered entity hospitals with brand medications in Tier 2 for therapeutic categories where FDA-approved generics exist. This formulary gap costs their 340B program significant acquisition dollars - revealing missed savings opportunities in their pharmaceutical procurement strategy.
Specific number (12 categories) shows analysis. Dollar amount is concrete and meaningful. Ties to 340B program shows understanding. Easy routing question. However, missing specifics - which 12 categories? Can't verify in 60 seconds. The $340K feels like multiplied stats without showing work.
Target 340B covered entity hospitals with brand-only formulary placement in cardiovascular categories where Rising has FDA-approved bioequivalent generics. Provide specific drug names and cost analysis showing savings opportunity by switching to generic Tier 1 placement.
Eight specific categories shows analysis. Named drugs (amlodipine/atorvastatin, olmesartan/HCTZ) are concrete. $180K is specific to cardiovascular spend. However, still feels promotional - "we have these products." The $180K calculation isn't transparent. Any cardiovascular generic supplier could send similar message.
Cross-reference Medicare Part D formulary exclusions with CMS prior authorization data to identify plans experiencing high PA volume in shortage-prone categories where they exclude generic alternatives. Show them how Rising manufactures excluded generics that could bypass PA requirements.
847 PAs is specific and verifiable via CMS data. Q3 2024 is concrete timeframe. 19 products is specific. However, the insight is "we have products you don't cover" - promotional. Any supplier with those NDCs could send this. Doesn't reveal something about THEM they don't know.
Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data to find companies in specific painful situations. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your Part D formulary (H3214) excludes 47 generics in shortage-prone categories" instead of "I see you're hiring pharmacy directors," you're not another sales email. You're the person who did the homework.
The messages above aren't templates. They're examples of what happens when you combine real data sources with specific situations. Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable public data. Here are the sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| HRSA 340B OPAIS Contract Pharmacy Directory | pharmacy_name, address, covered_entity_partner, contract_date | Identifying contract pharmacies serving multiple 340B covered entities |
| FDA Drug Shortage Database | drug_name, therapeutic_category, shortage_status, alert_date | Current shortage alerts by therapeutic category |
| CMS Medicare Part D Plan Directory | plan_name, contract_number, enrollment_numbers, service_area | Part D plan identification and contract numbers |
| CMS Prescription Drug Plan Formulary Data Files | formulary_medications, tier_placement, excluded_drugs, prior_auth_requirements | Formulary gaps, tier placement, generic exclusions |
| HRSA 340B Program Covered Entity Registry | covered_entity_name, entity_type, address, program_status | 340B hospital identification and eligibility verification |
| Hospital P&T Committee Meeting Minutes | meeting_date, formulary_decisions, therapeutic_categories_reviewed | Last formulary review dates, tier placement decisions |
| FDA Orange Book | drug_name, therapeutic_category, approval_date, bioequivalence_status | Generic approval status and new approvals by category |
| CMS Prior Authorization Data | plan_contract_number, therapeutic_category, PA_volume, quarter | Prior authorization volume by plan and category |
| CMS Special Focus Facility Designations | facility_name, designation_status, effective_date | Identifying covered entities under enhanced CMS scrutiny |